Inactive Instrument

Amryt Pharma plc

AMYT

US03217L1061

Amryt Pharma plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 04, 2022 at 07:00 am EDT

Amryt Pharma plc reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 68.54 million compared to USD 62.76 million a year ago. Net loss was USD 7.05 million compared to USD 6.8 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.2 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to USD 0.2 a year ago.
For the six months, sales was USD 127.67 million compared to USD 111.19 million a year ago. Net loss was USD 21.54 million compared to USD 23.34 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.35 compared to USD 0.65 a year ago.

Latest news about Amryt Pharma plc

Amryt Pharma plc(NasdaqGS:AMYT) dropped from S&P Global BMI Index	23-04-13	CI
Amryt Pharma plc(NasdaqGS:AMYT) dropped from NASDAQ Composite Index	23-04-12	CI
Chiesi Farmaceutici S.p.A. completed the acquisition of Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others.	23-04-11	CI
Amryt Pharma's Shareholders Approve Acquisition by Chiesi Farmaceutici	23-03-22	MT
Amryt Pharma plc’s Equity Buyback announced on March 9, 2022, has expired.	23-03-07	CI
HC Wainwright Downgrades Amryt Pharma to Neutral From Buy, Cuts Price Target to $14.50 From $18	23-01-18	MT
Maxim Group Downgrades Amryt Pharma to Hold From Buy	23-01-10	MT
Cantor Fitzgerald Downgrades Amryt Pharma to Neutral From Overweight, Adjusts Price Target to $14.75 From $25	23-01-10	MT
Canaccord Genuity Downgrades Amryt Pharma to Hold From Buy, Adjusts Price Target to $17 From $19	23-01-10	MT
Sector Update: Health Care Stocks Largely Struggle Monday	23-01-09	MT
Top Midday Gainers	23-01-09	MT
Sector Update: Health Care Stocks Struggling to Begin New Week	23-01-09	MT
Sector Update: Health Care	23-01-09	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	23-01-09	MT
Rate Hike Clues, China Border Reopening Fuel Gains for US Equity Futures	23-01-09	MT
Top Premarket Gainers	23-01-09	MT
Amryt Pharma to be Acquired by Chiesi Farmaceutici	23-01-09	MT
Italy's Chiesi Farmaceutici to Buy Rare Disease-focused Amryt Pharma for $1.5 Billion	23-01-09	MT
Chiesi Farmaceutici S.p.A. entered into a definitive agreement to acquire Amryt Pharma plc from Athyrium Capital Management, LP, Highbridge Capital Management, LLC, Joe Wiley, Rory Nealon, Ray Stafford and others for $1.1 billion.	23-01-07	CI
Amryt Pharma Says Phase 3 Trial of Cholesterol Disorder Treatment Met Primary Endpoint; Shares Gain Pre-Bell	23-01-05	MT
Amryt Announces Positive Top Line Results from Phase 3 Pediatric Trial of Lomitapide in HoFH	23-01-05	CI
Amryt Says European Medicines Agency Committee Adopts Positive Opinion on Orphan Designation for Mycapssa	22-12-19	MT
Amryt Pharma Receives Approval for Mycapssa in Europe	22-12-05	MT
Amryt Announces European Commission Approves Mycapssa® for the Treatment of Acromegaly	22-12-05	CI
Amryt Pharma Says It Received New US Patent for Mycapssa	22-11-30	MT

Chart Amryt Pharma plc

Duration

Period

More charts

Company Profile

Amryt Pharma plc is a commercial-stage biopharmaceutical company. It is focused on acquiring, developing, and commercializing novel treatments for rare diseases. Its commercial business comprises three orphan disease products, such as metreleptin (Myalept/ Myalepta); lomitapide (Juxtapid/ Lojuxta), and oral octreotide (Mycapssa). Myalept is approved in the United States as an adjunct to diet as replacement therapy to treat leptin deficiency in patients with congenital or acquired generalised lipodystrophy (GL). Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, homozygous familial hypercholesterolaemia (HoFH). Mycapssa is a combination of octreotide acetate and excipients, collectively called Transient Permeability Enhancer (TPE). Its development candidate, Oleogel-S10 (Filsuvez) is a treatment for the cutaneous manifestations of junctional and dystrophic (JEB and DEB) epidermolysis bullosa.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	-4.66%	87.53B
SAMSUNG BIOLOGICS CO.,LTD.	+2.63%	40.42B
BIOGEN INC.	-21.76%	29.48B
UCB	+56.02%	25.43B
BIOMARIN PHARMACEUTICAL INC.	-14.78%	15.59B
INCYTE CORPORATION	-18.49%	11.49B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-15.61%	11.1B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-44.02%	11.3B
SWEDISH ORPHAN BIOVITRUM AB	+4.12%	8.75B

Biopharmaceuticals